PharVision Advisers’s Nordson NDSN Stock Holding History

PharVision Advisers’s Portfolio NDSN Stock Details NDSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,241	Closed	-$480K	–	747
2025 Q2	$480K	Buy	+2,241	New	+$446K	0.69%	8

Other funds holding NDSN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PharVision Advisers's NDSN Position: Q3 2025 in Review

PharVision Advisers sold out of Nordson (NDSN) in Q3 2025, closing a stake of 2,241 shares — an estimated $480K sold.

PharVision Advisers first reported a position in NDSN in Q2 2025 and held it in 1 quarter. The position peaked at $480K in Q2 2025. 631 funds tracked by Wall St. Rank hold NDSN as of Q3 2025.

PharVision Advisers reported no remaining Nordson position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 2,241 Nordson shares in Q3 2025, an estimated $480K.
PharVision Advisers first reported a position in Nordson in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Nordson position peaked at $480K in Q2 2025.
631 funds tracked by Wall St. Rank held Nordson as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.